-

Axion BioSystems Continues Agreement Giving Corning® Exclusive Rights to Distribute Award-Winning Cell Counting Device

ATLANTA--(BUSINESS WIRE)--Axion BioSystems today announced an agreement with Corning Incorporated (NYSE: GLW) that continues Corning’s exclusive worldwide distribution rights for the Corning® Cell Counter. The simple yet powerful device, developed by Axion BioSystems and distributed by Corning, was recently included in the SelectScience® top 10 list of remarkable products advancing life science research. The agreement extends the successful collaboration between Corning and Axion BioSystems to bring essential, affordable lab tools to market and accelerate discovery.

“We look forward to extending our successful collaboration with Corning to distribute Axion’s cell counting device to scientists worldwide working to unlock the mechanisms of disease...,” said Axion BioSystems' CEO Julien Bradley.

Share

Cell counting is a critical step in biomedical research applications, clinical diagnostics, and cell therapy administration. Compared to tedious and time-consuming manual cell counting, the Corning Cell Counter offers superior speed and reproducibility and an unprecedented level of detail, allowing it to distinguish between cells and debris, detect individual cells within a cluster, or count three-dimensional organoids and measure their size.

“The Corning Cell Counter not only simplifies the workflow in cell culture laboratories but is also timesaving and more reliable than standard methods,” said Axion BioSystems CEO Julien Bradley. “We look forward to extending our successful collaboration with Corning to distribute Axion’s cell counting device to scientists worldwide working to unlock the mechanisms of disease and accelerate the development of groundbreaking therapeutics.”

Since launching the revolutionary Maestro multielectrode array (MEA) platform in 2008, Axion BioSystems has continuously expanded its line of next-generation live-cell analysis tools to meet the demands of today’s complex research. In addition to next-generation MEA systems and cell counters, the company’s portfolio also includes impedance-based analyzers, automated imaging systems, and high-quality consumables used in academic, pharmaceutical, and biotech labs around the world.

About Axion BioSystems

Axion BioSystems is a leading life sciences tools company focused on innovative live-cell assays used to study the function of cells in vitro for drug discovery and disease modeling. The team at Axion BioSystems is dedicated to continuing the advancement of new technologies that accelerate research and further the understanding of biological complexity outside of the body. Axion BioSystems is headquartered in Atlanta, Georgia, USA, and has offices worldwide. www.axionbiosystems.com

Contacts

Mike Clements
SVP Marketing & Corporate Strategy, Axion BioSystems
+1-678-469-3439
mclements@axionbio.com

Axion BioSystems


Release Versions

Contacts

Mike Clements
SVP Marketing & Corporate Strategy, Axion BioSystems
+1-678-469-3439
mclements@axionbio.com

Social Media Profiles
More News From Axion BioSystems

Harnessing Combined Expertise: STEMCELL Technologies and Axion BioSystems Partner to Streamline Culture and Analysis of Excitable Cells

ATLANTA & VANCOUVER, British Columbia--(BUSINESS WIRE)--Axion BioSystems and STEMCELL Technologies are pleased to announce a strategic partnership that will enable STEMCELL to sell Axion’s state-of-the-art Maestro Pro™ and Maestro Edge™ multielectrode array (MEA) systems within North America and Europe. The industry-leading Maestro MEA systems will also continue to be available for purchase worldwide directly from Axion BioSystems. Through this partnership, Axion and STEMCELL will enable scient...

Axion BioSystems Adds Affordable Maestro Volt™ to its Industry-Leading MEA System Lineup

ATLANTA--(BUSINESS WIRE)--Axion BioSystems today announced the launch of the new Maestro Volt™, an affordable benchtop microelectrode array (MEA) system designed to meet the demands of academic labs with lower throughput needs and limited budgets. Featuring the same ease of use, high-quality controls, and intuitive software synonymous with the Maestro name, the 6-well Maestro Volt is available for both neurological and cardiovascular research applications. The new device expands Axion’s flagshi...

Axion BioSystems Welcomes Biotech Industry Leader Julien Bradley as New CEO

ATLANTA--(BUSINESS WIRE)--Axion BioSystems, a leading life science tools company focused on advanced live-cell assay platforms, today announced the appointment of Julien Bradley as the company’s new Chief Executive Officer. With nearly 20 years of experience in biotechnology development, commercialization, and leadership, Bradley will build on Axion’s growth in the fields of stem cell research, immuno-oncology, cell-based therapies, and drug discovery. Bradley has held executive and senior lead...
Back to Newsroom